Eli Lilly stock soars on earnings, 'off-the-charts' demand for weight-loss drugs

Eli Lilly stock soars on earnings, 'off-the-charts' demand for weight-loss drugsПодробнее

Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more productПодробнее

Potential for Weight-Loss Drugs Boosts Eli LillyПодробнее

Eli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise ChenПодробнее

Eli Lilly and Novo can 'coexist for awhile' in the weight-loss drug space, says BMO's Evan SeigermanПодробнее

Weight Loss Drug Demand Skyrockets, Boosts Eli Lilly 2024 Revenue ForecastПодробнее

Eli Lilly stock soars following data suggesting its Alzheimer's drug can slow illnessПодробнее

Eli Lilly's Stock Exceeds Profit Forecast with High Weight Loss & Drug Demand #shortsПодробнее

Eli Lilly weight loss drugs are 'mega-growth assets' BMO's Evan Seigerman saysПодробнее

Why Eli Lilly Stock Is Breaking Out | IBD LiveПодробнее

Eli Lilly soars on profit outlook, demand for weight-loss drugПодробнее

Lilly breaks ground on massive factory in Germany 🇩🇪Подробнее

Eli Lilly (LLY) Might Not Meet Demand for Diabetes & Weight Loss DrugsПодробнее

Weight loss elixir is in short supply! Eli Lilly raised revenue guidelines, and stock prices soaredПодробнее

Eli Lilly beats on Q3 earnings, cites diabetes drug demandПодробнее

Eli Lilly’s Chart Gets Another Boost from Obesity DrugПодробнее

This Stock Went Up 100% in One Day. Why It's Important! #shorts #stocks #ozempic #obesitymedicineПодробнее

Eli Lilly CEO: We know there's high demand for weight-loss drugs and we're ready to meet itПодробнее

BofA's Geoff Meacham on Eli Lilly on Q4 results: The story has changed to diabetes and obesityПодробнее